Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01584284 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
A Phase 1 study, sponsored by Genelux Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01584284 is a Phase 1 study that has completed, run by Genelux Corporation. The registered enrollment target is 19 participants.
The verdict
NCT01584284, a Phase 1 study, has completed, sponsored by Genelux Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.
Interventions
- BIOLOGICAL GL-ONC1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01584284
The ClinicalTrials.gov registry entry for NCT01584284 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genelux Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GL-ONC1 is the first listed.
NCT01584284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01584284 about?
NCT01584284 is a clinical study titled "Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer". The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.
What is the current status of trial NCT01584284?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2012-04. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01584284?
The interventions under investigation include: GL-ONC1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01584284?
This trial is sponsored by Genelux Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.